The FDA has accepted a New Drug Application (NDA) for Celcuity’s gedatolisib in hormone receptor positive (HR+), human ...
A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...
Gedatolisib's NDA for advanced breast cancer treatment has been accepted by the FDA, with a priority review and a PDUFA date set for July 17, 2026. The drug is intended for HR+/HER2–, PIK3CA wild-type ...
News-Medical.Net on MSN
Atypical mutation offers clues to personalized pancreatic cancer treatment
A new study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...
FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026MINNEAPOLIS, (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: ...
TheFly reported on January 8 that Truist raised its price target on BBIO to $86 from $80 while maintaining a Buy rating.
A deep dive into the scientific shift toward multi-target obesity therapeutics and its implications for metabolic health and ...
The firm filed data from the Phase III VIKTORIA-1 trial, which evaluated gedatolisib with fulvestrant with or without a CDK4/6 inhibitor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback